Humoral Immune Responses in Patients with Severe COVID-19: A Comparative Pilot Study between Individuals Infected by SARS-CoV-2 during the Wild-Type and the Delta Periods

Since the onset of the COVID-19 pandemic, humanity has experienced the spread and circulation of several SARS-CoV-2 variants that differed in transmissibility, contagiousness, and the ability to escape from vaccine-induced neutralizing antibodies. However, issues related to the differences in the variant-specific immune responses remain insufficiently studied. The aim of this study was to compare the parameters of the humoral immune responses in two groups of patients with acute COVID-19 who were infected during the circulation period of the D614G and the Delta variants of SARS-CoV-2. Sera from 48 patients with acute COVID-19 were tested for SARS-CoV-2 binding and neutralizing antibodies using six assays. We found that serum samples from the D614G period demonstrated 3.9- and 1.6-fold increases in RBD- and spike-specific IgG binding with wild-type antigens compared with Delta variant antigens (p < 0.01). Cluster analysis showed the existence of two well-separated clusters. The first cluster mainly consisted of D614G-period patients and the second cluster predominantly included patients from the Delta period. The results thus obtained indicate that humoral immune responses in D614G- and Delta-specific infections can be characterized by variant-specific signatures. This can be taken into account when developing new variant-specific vaccines.

Авторы
Sukhova Maria1, 2 , Byazrova Maria 1, 2, 3 , Mikhailov Artem1, 2 , Yusubalieva Gaukhar4, 5 , Maslova Irina6 , Belovezhets Tatyana7 , Chikaev Nikolay7 , Vorobiev Ivan8 , Baklaushev Vladimir4, 5 , Filatov Alexander1, 2
Журнал
Издательство
MDPI AG
Номер выпуска
9
Язык
Английский
Страницы
2347
Статус
Опубликовано
Том
11
Год
2023
Организации
  • 1 Laboratory of Immunochemistry, National Research Center Institute of Immunology, Federal Medical Biological Agency of Russia, 115522 Moscow, Russia
  • 2 Department of Immunology, Faculty of Biology, Lomonosov Moscow State University, 119234 Moscow, Russia
  • 3 Department of Immunology, Peoples’ Friendship University of Russia (RUDN University) of Ministry of Science and Higher Education of the Russian Federation, 117198 Moscow, Russia
  • 4 Laboratory of Cell Technology, Federal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the FMBA of Russia, 115682 Moscow, Russia
  • 5 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
  • 6 Clinical Hospital #85, Federal Medical Biological Agency of Russia, 115409 Moscow, Russia
  • 7 Laboratory of Immunogenetics, Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia
  • 8 Laboratory of Mammalian Cell Bioengineering, Skryabin Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, 117312 Moscow, Russia
Ключевые слова
SARS-CoV-2; COVID-19; variants of concern; virus neutralization
Цитировать
Поделиться

Другие записи